open access to scientific and medical research

Back to Journals » Biologics: Targets and Therapy » Volume 6

Review

Noteworthy comment: Asthma is currently affecting about 235 million people, and is the most common chronic disease in children. It is now well appreciated that asthma is not a simple disease. Reclassifying asthma with identification of sub-phenotypes has great impacts on choosing appropriate therapeutic approaches for improved treatment outcomes. It suggests that proper target should be chosen for individualized therapy. Accordingly, careful patient profiling and selection for clinical trials are extremely important. Moreover, many times, surrogate markers have to be used in clinical practice. This manuscript provided an excellent instruction of how to wisely choose appropriate biomarker(s) for patient classification and proper target(s) for improved therapy.

Highly-accessed

Lebrikizumab in the personalized management of asthma

Total article views		HTML views	PDF downloads	Totals
20,281	Dovepress*	15,437+	3,410	18,847
	PubMed Central*	4,844	1,319	6,163
	Totals	20,281	4,729	25,010
*Since 14 September 2012 +Since July 2016

Total mentioned	Facebook	Delicious	Reddit	Twitter	Others
30	2	0	0	7	21

View citations on PubMed Central and Google Scholar